M&A

We work with entrepreneur-owned businesses, private equity-backed companies and large corporates on company sales, acquisitions, mergers and disposals. Our in-depth understanding of our sectors and of the global buyer universe enables us to think creatively about strategic positioning, identify interesting partners, manage complexity and deliver outstanding results. The majority of our deals are cross-border, with a mix of European, North American and Asian clients and counterparties.

Sellers: when the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business.

And for buyers: our global network and local presence, together with a deep analysis of evolving sector trends, opens up a plethora of opportunities to expand your reach — and outpace the competition.

M&A Deals

Nov 2022
has been acquired by
An Interlock Equity-backed company
Oct 2022
has been acquired by
A Trill Impact-backed company
Jul 2022
has received investment from
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
Has invested in
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
Apr 2022
has been acquired by
A company backed by TA Associates, HGGC, Charlesbank, Harvest Partners SCF
Apr 2022
has been acquired by
Mar 2022
An AlbionVC-backed company
has received investment from
Morgan Stanley Expansion Capital and Keyhaven Capital Partners co-invest
Mar 2022
has received investment from

Results. Great people creating great outcomes, together.

Latest Insights

Reports
23rd November 2022

Pharma Licensing – an introduction

We are pleased to share our introduction to Pharma Licensing. This guide provides an overview of both in and out-licensing as well as insights on what to anticipate during the process. We hope that you find this guide useful and look forward to discussing the underlying themes with you. Do get in touch! Click to […]

Insights
17th October 2022

Pharma Licensing: the why the how and a few things to get right

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]

Reports
17th October 2022

MedTech Services – Drivers of growth and consolidation

Welcome to our MedTech Services Report. This sets out our views on the tailwinds driving growth and increased outsourcing, an overview of the MedTech CDMO and CRO market as well as the key drivers of consolidation in the sector. We hope that you enjoy this report and look forward to discussing the data and underlying […]